| Drug Name |
Prucalopride |
| Drug ID |
BADD_D01874 |
| Description |
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] |
| Indications and Usage |
Investigated for use/treatment in constipation, ileus, and pediatric indications. |
| Marketing Status |
Not Available |
| ATC Code |
A06AX05 |
| DrugBank ID |
DB06480
|
| KEGG ID |
D09205
|
| MeSH ID |
C406662
|
| PubChem ID |
3052762
|
| TTD Drug ID |
D04QSJ
|
| NDC Product Code |
54092-547; 54092-546 |
| Synonyms |
prucalopride | 4-amino-5-chloro-N-(1-(3-methoxypropyl)-4-piperidinyl)-2,3-dihydro-1-benzofuran-7-carboxamide | motegrity | resotran | resotrans | R 093877 | R093877 | Resolor |
